Collegium Pharmaceutical Inc
NASDAQ:COLL
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
25.5
41.86
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one COLL stock under the Base Case scenario is 47.46 USD. Compared to the current market price of 31.19 USD, Collegium Pharmaceutical Inc is Undervalued by 34%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Collegium Pharmaceutical Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for COLL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Collegium Pharmaceutical Inc
Balance Sheet Decomposition
Collegium Pharmaceutical Inc
Current Assets | 443.8m |
Cash & Short-Term Investments | 120m |
Receivables | 228.5m |
Other Current Assets | 95.4m |
Non-Current Assets | 1.2B |
PP&E | 20.8m |
Intangibles | 1.1B |
Other Non-Current Assets | 77.7m |
Current Liabilities | 459.4m |
Accounts Payable | 3.1m |
Accrued Liabilities | 356.8m |
Other Current Liabilities | 99.5m |
Non-Current Liabilities | 941.4m |
Long-Term Debt | 802.6m |
Other Non-Current Liabilities | 138.8m |
Earnings Waterfall
Collegium Pharmaceutical Inc
Revenue
|
599.2m
USD
|
Cost of Revenue
|
-225.6m
USD
|
Gross Profit
|
373.7m
USD
|
Operating Expenses
|
-180.2m
USD
|
Operating Income
|
193.5m
USD
|
Other Expenses
|
-104.9m
USD
|
Net Income
|
88.6m
USD
|
Free Cash Flow Analysis
Collegium Pharmaceutical Inc
USD | |
Free Cash Flow | USD |
COLL Profitability Score
Profitability Due Diligence
Collegium Pharmaceutical Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Collegium Pharmaceutical Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
COLL Solvency Score
Solvency Due Diligence
Collegium Pharmaceutical Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Score
Collegium Pharmaceutical Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
COLL Price Targets Summary
Collegium Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for COLL is 43.1 USD with a low forecast of 37.37 USD and a high forecast of 52.5 USD.
Dividends
Current shareholder yield for COLL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
COLL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
Contact
IPO
Employees
Officers
The intrinsic value of one COLL stock under the Base Case scenario is 47.46 USD.
Compared to the current market price of 31.19 USD, Collegium Pharmaceutical Inc is Undervalued by 34%.